Roy Bruce, Cordova Francis C, Travaline John M, D'Alonzo Gilbert E, Criner Gerard J
Division of Pulmonary and Critical Care Medicine, 3401 N Broad St, Philadelphia, PA 19140-5103, USA.
J Am Osteopath Assoc. 2007 Apr;107(4):148-56.
Noninvasive positive-pressure ventilation (NPPV) is commonly used to improve ventilation and oxygenation in patients with acute respiratory failure (ARF). Mask leak and intolerance due to facial discomfort or claustrophobia often occur with NPPV and are frequently cited reasons for treatment failure.
Retrospective review of patient records from a tertiary-care referral hospital.
We report the effectiveness of a full face mask in the application of NPPV for 10 nonambulatory patients (mean [SD], 61 [9] years) who had a combined total of 13 episodes of ARF. After these patients were unable to receive NPPV therapy via the more commonly available nasal or oronasal masks, care was provided using full face masks. Eight of 10 patients had hypercapnic respiratory failure; 2 patients, hypoxemic respiratory failure. All patients were placed on ventilation initially using a bi-level positive airway pressure device. Subsequently, patient ventilation was achieved using a Puritan Bennett 7200a ventilator for on-line respiratory monitoring. The mean (SD) duration of treatment with NPPV was 9.7 (2.7) hours per day for 3.0 (1.6) days. Following NPPV via full face mask, the patients' Paco(2) decreased (65 [20] vs 82 [27] mm Hg, P=.09) and pH increased significantly (7.36 [0.07] vs 7.26 [0.07], P<.05) in less than 2 hours. Moreover, the patients demonstrated decreased respiratory rate (18 [7] vs 32 [8] breaths/min, P<.01), heart rate (106 [13] vs 124 [16] beats/min, P=.008), and Acute Physiology and Chronic Health Evaluation II scores (12 [3] vs 17 [4], P<.005) after NPPV via full face mask. These cardiorespiratory alterations occurred as early as 1 hour after NPPV initiation and were maintained throughout treatment. Two patients required endotracheal intubation because of copious purulent secretions.
For individuals with hypercapnic respiratory failure who cannot tolerate NPPV using nasal or oronasal masks, use of full face masks may improve outcomes, allowing physicians to avoid ordering endotracheal intubation and mechanical ventilation.
无创正压通气(NPPV)常用于改善急性呼吸衰竭(ARF)患者的通气和氧合。NPPV常出现面罩漏气以及因面部不适或幽闭恐惧症导致的不耐受情况,这也是治疗失败的常见原因。
对一家三级转诊医院的患者记录进行回顾性分析。
我们报告了全脸面罩在10例非卧床患者(平均[标准差],61[9]岁)应用NPPV中的有效性,这些患者共发生13次ARF发作。在这些患者无法通过更常用的鼻罩或口鼻面罩接受NPPV治疗后,使用全脸面罩进行护理。10例患者中有8例为高碳酸血症性呼吸衰竭;2例为低氧血症性呼吸衰竭。所有患者最初使用双水平气道正压装置进行通气。随后,使用Puritan Bennett 7200a呼吸机进行患者通气以进行在线呼吸监测。NPPV治疗的平均(标准差)持续时间为每天9.7(2.7)小时,共3.0(1.6)天。通过全脸面罩进行NPPV后,患者的动脉血二氧化碳分压(Paco₂)在不到2小时内下降(65[20]对82[27]mmHg,P = 0.09),pH值显著升高(7.36[0.07]对7.26[0.07],P < 0.05)。此外,通过全脸面罩进行NPPV后,患者的呼吸频率(18[7]对32[8]次/分钟,P < 0.01)、心率(106[13]对124[16]次/分钟,P = 0.008)和急性生理与慢性健康状况评估II(APACHE II)评分(12[3]对17[4],P < 0.005)均下降。这些心肺功能改变在NPPV开始后1小时就出现,并在整个治疗过程中持续存在。2例患者因大量脓性分泌物需要气管插管。
对于不能耐受使用鼻罩或口鼻面罩进行NPPV的高碳酸血症性呼吸衰竭患者,使用全脸面罩可能会改善治疗效果,使医生避免进行气管插管和机械通气。